Mugitani A - Search Results

1

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K. Shinohara Y, et al. Among authors: mugitani a. Haematologica. 2013 Sep;98(9):1407-13. doi: 10.3324/haematol.2013.085167. Epub 2013 May 28. Haematologica. 2013. PMID: 23716542 Free PMC article. Clinical Trial.

2

Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest.

Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T, Hino M. Makita K, et al. Among authors: mugitani a. Bone Marrow Transplant. 2004 Mar;33(6):661-5. doi: 10.1038/sj.bmt.1704394. Bone Marrow Transplant. 2004. PMID: 14716337

3

[Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].

Yamamura R, Yamane T, Aoyama Y, Nakamae H, Hasegawa T, Ohta K, Nakao Y, Ohta T, Mugitani A, Hino M. Yamamura R, et al. Among authors: mugitani a. Gan To Kagaku Ryoho. 2004 Mar;31(3):373-5. Gan To Kagaku Ryoho. 2004. PMID: 15045943 Japanese.

4

[High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].

Yamane T, Hirose A, Nakajima Y, Nakane T, Koh H, Takeoka Y, Nakamae M, Yamamura R, Nakamae H, Nakao Y, Mugitani A, Yagi T, Teshima H, Hino M. Yamane T, et al. Among authors: mugitani a. Gan To Kagaku Ryoho. 2006 Feb;33(2):193-8. Gan To Kagaku Ryoho. 2006. PMID: 16484855 Japanese.

5

[Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].

Hong H, Aoyama Y, Yamamura R, Ohta T, Mugitani A, Yamane T, Hino M, Matsumoto M, Fujimura Y. Hong H, et al. Among authors: mugitani a. Rinsho Ketsueki. 2006 Dec;47(12):1528-32. Rinsho Ketsueki. 2006. PMID: 17233471 Japanese.

6

The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, Matsuura Y, Wakita H, Matsuda M, Sakamoto E, Kiguchi T, Urabe A, Tamura K, Kanamaru A, Masaoka T. Ito Y, et al. Among authors: mugitani a. Int J Hematol. 2007 Feb;85(2):121-7. doi: 10.1532/IJH97.06079. Int J Hematol. 2007. PMID: 17321989 Clinical Trial.

7

[Multicentric Castleman disease-like case characterized by lymphadenopathy and polyclonal hypergammaglobulinemia associated with so-called Mikulicz disease].

Ohta T, Furukawa Y, Aoyama Y, Kumura T, Mugitani A, Nakamae H, Koh K, Yamane T, Hino M. Ohta T, et al. Among authors: mugitani a. Rinsho Ketsueki. 2007 Mar;48(3):229-34. Rinsho Ketsueki. 2007. PMID: 17441481 Japanese.

8

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.

Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M. Terada Y, et al. Among authors: mugitani a. J Exp Clin Cancer Res. 2009 Aug 19;28(1):116. doi: 10.1186/1756-9966-28-116. J Exp Clin Cancer Res. 2009. PMID: 19689822 Free PMC article.

9

[Complication of pernicious anemia during interferon-β treatment for type C chronic hepatitis].

Ichihara H, Koh S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Terada Y, Yamane T, Hino M, Mugitani A. Ichihara H, et al. Among authors: mugitani a. Rinsho Ketsueki. 2012 Mar;53(3):352-6. Rinsho Ketsueki. 2012. PMID: 22499054 Review. Japanese.

10

Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.

Nagasaki J, Aoyama Y, Hino M, Ido K, Ichihara H, Manabe M, Ohta T, Mugitani A. Nagasaki J, et al. Among authors: mugitani a. Acta Haematol. 2017;137(1):32-39. doi: 10.1159/000452732. Epub 2016 Nov 19. Acta Haematol. 2017. PMID: 27866185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page